Oxetane

Oxetane have a rapidly growing interest in medicinal chemistry as a tool for fine-tuning the physicochemical and pharmacokinetic properties of drug candidates. These four-membered oxygen-containing rings are valued for their ability to modulate key physicochemical properties including polarity, lipophilicity, and metabolic stability; their incorporation can improve aqueous solubility, reduce metabolic liability, reduce the basicity of adjacent amines, and redirect metabolic clearance away from cytochrome P450 enzymes. The oxetane ring serves as a hydrogen bond acceptor with a geometry distinct from carbonyl and ether analogues, and has been validated as a bioisostere for gem-dimethyl groups, ketones, and amides, with substitution patterns that reduce CYP-mediated oxidation at metabolically vulnerable positions while maintaining or improving binding affinity. The pronounced ring strain and high polarity of the oxetane introduce three-dimensionality into otherwise flat or conformationally flexible molecular frameworks, an increasingly valued property in programmes targeting protein-protein interactions and allosteric sites where flat, aromatic-rich molecules show poor selectivity. The synthetic accessibility of oxetane building blocks has advanced considerably in recent years through strain-release reactions, photocycloadditions, and flow chemistry approaches, enabling systematic introduction of the ring at a variety of substitution positions, including as a scaffold element rather than purely as a peripheral physicochemical modifier.

Examples of Oxetane-containing compounds in the clinic include Rilzabrutinib (Wayrilz, Sanofi) is an FDA-approved oral reversible covalent BTK inhibitor approved in August 2025 as the first BTK inhibitor for persistent or chronic immune thrombocytopenia, and the first fully synthetic small-molecule drug in which a pendant oxetane ring was deliberately incorporated to reduce hERG channel interaction and modulate the basicity of an adjacent amine without sacrificing potency or selectivity. Orlistat (Xenical, Roche) is an FDA-approved gastric and pancreatic lipase inhibitor built around a β-lactone (2-oxetanone) warhead confirmed in the FDA label IUPAC name as the (2S,3S)-3-hexyl-4-oxo-2-oxetanyl moiety, approved in April 1999 for obesity management as the first antiobesity agent approved for long-term therapy that does not primarily alter central neurotransmitter concentrations, where the strained four-membered lactone ring forms a covalent ester bond with the catalytic serine residue of luminal lipases to block hydrolysis and absorption of approximately 30% of dietary fat, and metabolic ring opening of the β-lactone abolishes inhibitory activity, directly confirming the structural indispensability of the intact oxetanone.

Our range of Oxetanes features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies.

Please examine a selection of Oxetanes in our catalogue. The full range can be found using the substructure feature of our Search tools.